Nature Communications (Mar 2023)
The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma
Abstract
Immunotherapy resistance is common among melanoma patients. Here, the authors identify three resistance mechanism subtypes across tumor-derived cell lines and matched samples and highlight antigen presentation disruption as a key mediator of resistance.